DK4034535T3 - Aza-quinolinforbindelser og anvendelser deraf - Google Patents

Aza-quinolinforbindelser og anvendelser deraf

Info

Publication number
DK4034535T3
DK4034535T3 DK20868772.3T DK20868772T DK4034535T3 DK 4034535 T3 DK4034535 T3 DK 4034535T3 DK 20868772 T DK20868772 T DK 20868772T DK 4034535 T3 DK4034535 T3 DK 4034535T3
Authority
DK
Denmark
Prior art keywords
aza
quinoline compounds
quinoline
compounds
Prior art date
Application number
DK20868772.3T
Other languages
Danish (da)
English (en)
Inventor
Xuan Dai
Michael Dore
Xiang-Ju Justin Gu
Kevin Kun Chin Liu
Sing Yeung Frankie Mak
Yuan Mi
Counde Oyang
Julien Papillon
Wei Qi (Vicky)
Xiaoxia Yan
Zhengtian Yu
Ji Yue Zhang (Jeff)
Kehao Zhao
Ling Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK4034535T3 publication Critical patent/DK4034535T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK20868772.3T 2019-09-26 2020-09-24 Aza-quinolinforbindelser og anvendelser deraf DK4034535T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019108296 2019-09-26
PCT/CN2020/117487 WO2021057853A1 (en) 2019-09-26 2020-09-24 Aza-quinoline compounds and uses thereof

Publications (1)

Publication Number Publication Date
DK4034535T3 true DK4034535T3 (da) 2026-04-07

Family

ID=75166744

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20868772.3T DK4034535T3 (da) 2019-09-26 2020-09-24 Aza-quinolinforbindelser og anvendelser deraf

Country Status (11)

Country Link
US (2) US12544374B2 (cg-RX-API-DMAC7.html)
EP (1) EP4034535B1 (cg-RX-API-DMAC7.html)
JP (1) JP7763753B2 (cg-RX-API-DMAC7.html)
KR (1) KR102889562B1 (cg-RX-API-DMAC7.html)
CN (1) CN114746414B (cg-RX-API-DMAC7.html)
AU (1) AU2020355837B2 (cg-RX-API-DMAC7.html)
CA (1) CA3150284A1 (cg-RX-API-DMAC7.html)
DK (1) DK4034535T3 (cg-RX-API-DMAC7.html)
ES (1) ES3067468T3 (cg-RX-API-DMAC7.html)
IL (1) IL291499B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021057853A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4034535T3 (da) 2019-09-26 2026-04-07 Novartis Ag Aza-quinolinforbindelser og anvendelser deraf
AR123185A1 (es) * 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
AR128015A1 (es) * 2021-12-16 2024-03-20 Transthera Sciences Nanjing Inc Inhibidor de cdk9 y uso del mismo
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
CN118515653B (zh) * 2024-07-23 2024-12-10 西湖制药(杭州)有限公司 一种ezh2特异性抑制剂及其制备方法和用途
CN118598873B (zh) * 2024-08-07 2024-11-19 艾斯拓康生物医药(天津)有限公司 一种手性的氮杂-喹啉类化合物的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Mek阻害剤による関節炎の治療
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
CA2478065C (en) 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
WO2014155301A1 (en) 2013-03-26 2014-10-02 Piramal Enterprises Limited Substituted bicyclic compounds as inhibitors of ezh2
MX375970B (es) 2014-12-23 2025-03-06 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos.
TW201708210A (zh) 2015-06-30 2017-03-01 葛蘭素史克智慧財產(第二)有限公司 Zeste同源物2增強子之抑制劑
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
MX2019004950A (es) 2016-10-28 2019-09-26 Icahn School Med Mount Sinai Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2.
DK4034535T3 (da) 2019-09-26 2026-04-07 Novartis Ag Aza-quinolinforbindelser og anvendelser deraf

Also Published As

Publication number Publication date
CN114746414B (zh) 2024-10-18
JP7763753B2 (ja) 2025-11-04
EP4034535A1 (en) 2022-08-03
CN114746414A (zh) 2022-07-12
US20260076968A1 (en) 2026-03-19
KR20220070229A (ko) 2022-05-30
US12544374B2 (en) 2026-02-10
AU2020355837B2 (en) 2025-10-02
IL291499B1 (en) 2025-04-01
WO2021057853A1 (en) 2021-04-01
KR102889562B1 (ko) 2025-11-24
AU2020355837A1 (en) 2022-02-24
IL291499B2 (en) 2025-08-01
CA3150284A1 (en) 2021-04-01
US20220280509A1 (en) 2022-09-08
ES3067468T3 (en) 2026-05-22
JP2022550353A (ja) 2022-12-01
EP4034535B1 (en) 2026-03-04
EP4034535A4 (en) 2023-11-22
IL291499A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
IL285178A (en) Compounds and uses thereof
DK3917616T3 (da) Heterocykliske forbindelser og anvendelse deraf
DK3946464T3 (da) Forbindelser og konjugater deraf
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
IL285461A (en) Processes and compounds
EP3994692C0 (en) BINARY COMPUTING CELL IN MEMORY
IL282998A (en) Pyridazinone compounds and uses thereof
IL278122B1 (en) Pteridinone compounds and uses thereof
DK4196479T5 (da) Substituerede pyridotriazinforbindelser og anvendelser deraf
EP3930851A4 (en) COMBINATION THERAPIES
EP3919491C0 (en) AKT INHIBITOR
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
DK3922266T3 (da) Toll-like-receptor-7- eller -8-agonist-kolesterolkompleks og anvendelse deraf
IL285118A (en) Compounds and uses thereof
EP3967649C0 (en) LIPID NANOPARTICLE
DK3892621T3 (da) Haloallylaminforbindelser og anvendelse deraf
DK3784666T3 (da) Antiproliferationsforbindelser og anvendelser deraf
DK3966226T3 (da) Masp-hæmmende forbindelser og anvendelser deraf
EP3912517C0 (en) FRAME
DK3919498T6 (da) Pyrrolopyrimidinderivat og anvendelse deraf
EP3957391C0 (en) AGITATOR
DK3932909T3 (da) Benzoindazolonforbindelse og mellemprodukt heraf
EP3962498A4 (en) Combination therapies
DK3573611T3 (da) Amidforbindelser og anvendelse deraf
EP3965638C0 (en) VAGINAL SPECULUM